Reshma Kewalramani
2019
Compensation breakdown
Non-Equity Incentive Plan | $1,260,000 |
---|---|
Option Awards | $1,575,011 |
Salary | $702,308 |
Stock Awards | $3,215,952 |
Other | $63,665 |
Total | $6,816,936 |
Kewalramani received $3.2M in stock awards, accounting for 47% of the total pay in 2019.
Kewalramani also received $1.3M in non-equity incentive plan, $1.6M in option awards, $702.3K in salary and $63.7K in other compensation.
Rankings
In 2019, Reshma Kewalramani's compensation ranked 1,428th out of 13,971 executives tracked by ExecPay. In other words, Kewalramani earned more than 89.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,428 | 90th |
Manufacturing | 504 | 91st |
Chemicals And Allied Products | 153 | 93rd |
Drugs | 121 | 94th |
Pharmaceutical Preparations | 91 | 94th |
Kewalramani's colleagues
We found six more compensation records of executives who worked with Reshma Kewalramani at Vertex Pharmaceuticals in 2019.
2019
Jeffrey Leiden
Vertex Pharmaceuticals
Chairman
2019
Stuart Arbuckle
Vertex Pharmaceuticals
EVP & Chief Commercial Officer
2019
Amit Sachdev
Vertex Pharmaceuticals
EVP & Chief Patient Officer
2019
Charles Wagner
Vertex Pharmaceuticals
Chief Financial Officer
2019
Paul Silva
Vertex Pharmaceuticals
SVP & Corporate Controller
2019
Ian Smith
Vertex Pharmaceuticals